Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC

Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.

Stephanie L. Graff, MD, director, breast oncology, Lifespan Cancer Institute, assistant professor of medicine, Warren Alpert Medical School, co-leader, Breast Cancer Translational Research Disease Group, Brown University’s Legorreta Cancer Center, discusses current and planned investigations of the emerging antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) in patients with metastatic hormone receptor (HR)–positive breast cancer and triple-negative breast cancer (TNBC).

There is substantial interest in developing the emerging Trop-2–targeting ADC Dato-DXd within the breast cancer space. Previous data on this agent’s use in patients with advanced solid tumors were reported from the phase 1 TROPION-PanTumor01 trial (NCT03401385), Graff begins. The multicenter dose-escalation/expansion trial included those with non–small cell lung cancer, as well as those with metastatic TNBC and HR-positive, HER2-negative breast cancer.

Data from an updated analysis of the TNBC cohort (n = 44) presented at the 2022 San Antonio Breast Cancer Symposium showed that Dato-DXd elicited objective responses in patients with heavily pretreated metastatic TNBC regardless of whether they had previously undergone treatment with topoisomerase I inhibitor–based ADCs, Graff reports. In patients who had progressed on standard treatment, Dato-DXd elicited an objective response rate (ORR) of 32%; this was comprised of 1 complete response (CR) and 13 partial responses (PR). The subgroup of patients who had been treated with topoisomerase I inhibitor–based ADCs (n = 27) experienced an ORR of 44%, which included 1 CR and 11 PRs. Results from the HR-positive, HER2-negative cohort of the trial also experienced encouraging and durable responses with Dato-DXd, according to Graff.

Results from TROPION-PanTumor01 have supported the launch of several ongoing trials that will continue investigating Dato-DXd in these spaces, Graff adds. For example, the phase 3 TROPION-Breast02 trial (NCT05374512) will further evaluate the efficacy and safety of Dato-DXd in patients with TNBC. Additionally, the phase 3 TROPION-Breast01 study (NCT05104866) will compare Dato-DXd with physician’s choice of treatment in patients with metastatic HR-positive breast cancer who have progressed on prior endocrine therapy and 1 or 2 prior lines of chemotherapy.

Disclosures: Dr Graff reports serving in a consultory or advisory role for AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Novartis, Pfizer, Seattle Genetics.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD